Stock events for Krystal Biotech, Inc. (KRYS)
Krystal Biotech's stock price has been impacted by several key events. In September 2025, the FDA approved a label update for VYJUVEK, expanding its use and allowing at-home application, and VYJUVEK launched in Germany, France and Japan. On November 3, 2025, the company held its Third Quarter 2025 Earnings Call. On January 8, 2026, Krystal Biotech provided a clinical data update for KB407. On January 12, 2026, the company provided a business update at the J.P. Morgan Healthcare Conference, reporting preliminary Q4 2025 VYJUVEK net revenue of $106M–$107M and full-year 2025 revenue of $388M–$389M. On February 17, 2026, Krystal Biotech announced its Fourth Quarter and Full Year 2025 Financial and Operating Results, reporting strong VYJUVEK revenue and regulatory milestones. On March 3, 2026, Krystal Biotech presented at the TD Cowen 46th Annual Health Care Conference.
Demand Seasonality affecting Krystal Biotech, Inc.’s stock price
There is no indication of significant demand seasonality for Krystal Biotech's products and services. Demand for specialized genetic medicines is driven by patient diagnosis and treatment initiation, rather than seasonal fluctuations.
Overview of Krystal Biotech, Inc.’s business
Krystal Biotech is a commercial-stage biotechnology company focused on genetic medicines for rare diseases, operating in the healthcare sector. Its core business uses a redosable Herpes Simplex Virus vector platform for gene therapies. Its major commercial product is VYJUVEK, a topical gene therapy for Dystrophic Epidermolysis Bullosa (DEB). VYJUVEK delivers copies of the COL7A1 gene to enable the production of normal COL7 protein. The company has a pipeline of product candidates including KB407 in Phase 1 for Cystic Fibrosis, KB408 in Phase 1 for Alpha-1 Antitrypsin Deficiency, KB707 in Phase 1/2 for solid tumors, KB105 for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis, KB801 for neurotrophic keratitis, KB803 for ocular complications of dystrophic epidermolysis bullosa, KB111 for Hailey-Hailey disease, and KB301 and KB304 in Phase 2 for aesthetic skin conditions and dynamic wrinkles.
KRYS’s Geographic footprint
Krystal Biotech manufactures, markets, and sells VYJUVEK in the United States. The company is expanding globally, with VYJUVEK approved in Japan and Europe, and launches underway in Germany, France, and Japan in late 2025.
KRYS Corporate Image Assessment
Krystal Biotech has a strong brand reputation due to its innovative approach to genetic medicine and the successful commercialization of VYJUVEK. The company is recognized for addressing diseases with high unmet medical needs. Analyst sentiment is positive, with a consensus of "Moderate Buy". The successful global expansion of VYJUVEK and positive clinical readouts have bolstered its reputation as a "Gene Therapy Trailblazer."
Ownership
Krystal Biotech has a concentrated ownership structure, with institutional investors holding over 86% of shares. Major institutional owners include BlackRock, Inc., The Vanguard Group, Inc., State Street Global Advisors, Inc., FMR LLC, Avoro Capital Advisors LLC, Soleus Capital Management, L.P., Capital Research and Management Company, Frazier Life Sciences Management, LP, Redmile Group, LLC, and Citadel Advisors LLC. Company insiders hold around 11.86% of shares.
